Microbial Production of Recombinant Rennet

2018 ◽  
pp. 222-233 ◽  
Author(s):  
Zumrut Begum Ogel
Keyword(s):  
Proteolytic Activity ◽  
Recombinant Dna ◽  
Microbial Production ◽  
Recombinant Dna Technology ◽  
Aspartic Proteases ◽  
The Past ◽  
Traditional Cheese ◽  
Dna Technology ◽  
Cheese Products ◽  
Recombinant Dna Techniques

Rennet, traditionally obtained from calves, is non-vegeterian and unethical due to the slaughter of unweaned animals. Chymosin is highly specific to the Phe105-Met106 bond of κ-casein and has low proteolytic activity. Microbial aspartic proteases can partly replace chymosin. However, recombinant DNA technology has allowed chymosin itself to be produced by bacteria, yeast, and molds. Not only rennet from calf, but from animals like goat kid, lamb, buffalo, camel, and others can be used in cheesemaking. Chymosins of these animals can be cloned and successfully expressed in microorganisms and can be employed in the production of novel as well as traditional cheese products from the milk of camel, goat, and even horse and donkey. This chapter outlines the recombinant DNA techniques applied over the past few years to improve the microbial production of recombinant rennet, from animals and plants.

Recombination in yeast and the recombinant DNA technology

Genome ◽  
1989 ◽  
Vol 31 (2) ◽  
pp. 536-540 ◽  
Author(s):  
Thomas D. Petes ◽  
Peter Detloff ◽  
Sue Jinks-Robertson ◽  
S. Renee Judd ◽  
Martin Kupiec ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Gene Conversion ◽  
Recombinant Dna ◽  
Recombinant Dna Technology ◽  
Yeast Saccharomyces Cerevisiae ◽  
Eukaryotic Genes ◽  
Dna Technology ◽  
Recombinant Dna Techniques ◽  
Repeated Genes

The development of methods to isolate eukaryotic genes, alter these genes in vitro and reintroduce them into the cell has had a major impact on the study of recombination in the yeast Saccharomyces cerevisiae. In this paper we discuss how recombinant DNA techniques have been employed in the study of recombination in yeast and the results that have been obtained in these studies.Key words: recombination, Saccharomyces cerevisiae, gene conversion, repeated genes.

scholarly journals Role of Recombinant DNA Technology to Improve Life

2016 ◽  
Vol 2016 ◽  
pp. 1-14 ◽  
Author(s):  
Suliman Khan ◽  
Muhammad Wajid Ullah ◽  
Rabeea Siddique ◽  
Ghulam Nabi ◽  
Sehrish Manan ◽  
...  
Keyword(s):  
Target Genes ◽  
Recombinant Dna ◽  
Human Life ◽  
Product Yield ◽  
Past Century ◽  
Recombinant Dna Technology ◽  
The Past ◽  
Genetic Modifications ◽  
Dna Technology

In the past century, the recombinant DNA technology was just an imagination that desirable characteristics can be improved in the living bodies by controlling the expressions of target genes. However, in recent era, this field has demonstrated unique impacts in bringing advancement in human life. By virtue of this technology, crucial proteins required for health problems and dietary purposes can be produced safely, affordably, and sufficiently. This technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, enhancing food resources, and resistance to divergent adverse environmental effects. Particularly in agriculture, the genetically modified plants have augmented resistance to harmful agents, enhanced product yield, and shown increased adaptability for better survival. Moreover, recombinant pharmaceuticals are now being used confidently and rapidly attaining commercial approvals. Techniques of recombinant DNA technology, gene therapy, and genetic modifications are also widely used for the purpose of bioremediation and treating serious diseases. Due to tremendous advancement and broad range of application in the field of recombinant DNA technology, this review article mainly focuses on its importance and the possible applications in daily life.

From animals in the service of nutrition...to the potential of biotechnology

1997 ◽  
Vol 78 (s2) ◽  
pp. S125-S133
Author(s):  
Judith Hall
Keyword(s):  
Animal Models ◽  
Recombinant Dna ◽  
Human Nutrition ◽  
Western World ◽  
Past Century ◽  
Recombinant Dna Technology ◽  
The Past ◽  
Nutrition Research ◽  
Dna Technology ◽  
Obesity And Cancer

In 1986, in her paper, ‘Animals in the service of human nutrition’, celebrating the award of the E. V. McCollum International Lectureship in Nutrition, Dr Elsie Widdowson observed: ‘Animals have served human nutrition well over the past century.... They are still of great service in human nutrition and may be more essential in the future as proper animal models for human diseases are discovered’. Ten years on, those animal models are an integral part of nutrition research and are providing fundamental tools to study the effects of diet on many of the major diseases of the Western world, including cardiovascular disease, obesity and cancer. Many of these models have been developed through the use of recombinant DNA technology and the expression of normal or mutated genes in the genome of transgenic mice.

scholarly journals NGO war on biotechnology

2005 ◽  
Vol 11 (3) ◽  
Author(s):  
Henry I Miller ◽  
Gregory Conko
Keyword(s):  
Genetic Modification ◽  
Recombinant Dna ◽  
Molecular Genetic ◽  
Significant Risk ◽  
Environmental Safety ◽  
Recombinant Dna Technology ◽  
Risks And Benefits ◽  
Dna Technology ◽  
Recombinant Dna Techniques ◽  
The Cost

Discussions of the risks and benefits of recombinant DNA technology, or 'genetic modification' (GM), should occur within the context of experience with older, 'conventional' techniques for genetic improvement. But critics' alarmist reports and commentaries invariably emphasise the things that might go wrong only with recombinant DNA-modified organisms, while studiously avoiding the essential broader context. They ignore vast amounts of data, including literally millennia of experience with less precise methods used for genetic modification, and they continue to deny the well-established scientific consensus that no unique risks attend the use of recombinant DNA techniques. They promulgate the perception that recombinant DNA technology is unproven, untested and unregulated – and promote an approach to regulation in which there is an inverse relationship between degree of scrutiny and risk. The disproportionate regulation of the products of recombinant DNA technology needlessly raises the cost of research and development, while it fails to advance consumer or environmental safety. The question we must ask is not whether regulation generally is or is not justified, but rather what should be regulated and how? The use of certain techniques – in particular, those that are the most precise and predictable – as a trigger for regulation cannot be justified scientifically. Regulatory efforts should be redirected to focus oversight on new organisms that express characteristics likely to pose significant risk, regardless of the methods used in their development, while leaving relatively low-risk traits of both classical and molecular genetic modification unburdened by costly regulation.

scholarly journals Current and future prospects for the global biotechnology industry

10.5912/jcb68 ◽  
1969 ◽  
Vol 10 (2) ◽  
Author(s):  
Faiz Kermani ◽  
Pietro Bonacossa
Keyword(s):  
New Zealand ◽  
Recombinant Dna ◽  
Biotechnology Industry ◽  
New Drugs ◽  
Future Prospects ◽  
Recombinant Dna Technology ◽  
The Past ◽  
The Usa ◽  
Biotechnology Companies ◽  
Dna Technology

The number of biotechnology compounds has been increasing steadily over the past 20 years, reflecting the key contribution that biotechnology is now making to healthcare. Recombinant DNA technology has been used to develop a number of therapeutic proteins, including antibodies, cytokines, hormones and vaccines for use in tackling and diagnosing a range of disorders. Worldwide there are more than 4,000 specialised biotechnology companies. The most well-known companies are located in the USA and Europe, but there are significant companies emerging in Canada, Australia, New Zealand and throughout Asia – particularly in Japan. Most of these companies are small in size and limited when it comes to finances and this has had an impact on the output of the industry in terms of new drugs.

scholarly journals Biotin Production by Using Recombinant DNA Technology

1992 ◽  
Vol 38 (Special) ◽  
pp. 263-266
Author(s):  
O. IFUKU ◽  
S. HAZE ◽  
J. KISHIMOTO ◽  
M. YANAGI
Keyword(s):  
Recombinant Dna ◽  
Recombinant Dna Technology ◽  
Dna Technology
Sign in / Sign up

Export Citation Format

Share Document